NASDAQ:NRSN NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis $0.76 -0.01 (-1.02%) Closing price 04:00 PM EasternExtended Trading$0.76 0.00 (0.00%) As of 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About NeuroSense Therapeutics Stock (NASDAQ:NRSN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NRSN alerts:Sign Up Key Stats Today's Range$0.75▼$0.7850-Day Range$0.69▼$0.9552-Week Range$0.63▼$2.28Volume56,618 shsAverage Volume159,596 shsMarket Capitalization$24.75 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingModerate Buy Company Overview NeuroSense Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system. At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration. By combining high-throughput screening with advanced medicinal chemistry and in vivo disease models, the company is advancing multiple small-molecule preclinical candidates toward Investigational New Drug (IND)-enabling studies. Key areas of focus include Alzheimer’s disease, Parkinson’s disease and other brain disorders linked to aging and cellular dysfunction. Founded by a team of neuroscientists and drug-discovery experts, NeuroSense is headquartered in Tel Aviv, Israel, with research operations extending to the United States. The company has established collaborations with leading academic institutions and contract research organizations to support its pipeline development. NeuroSense’s executive leadership brings extensive experience in biotechnology and pharmaceutical development, positioning the firm to translate its innovative science into potential new treatments for patients worldwide.AI Generated. May Contain Errors. Read More NeuroSense Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreNRSN MarketRank™: NeuroSense Therapeutics scored higher than 90% of companies evaluated by MarketBeat, and ranked 58th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingNeuroSense Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNeuroSense Therapeutics has a consensus price target of $8.50, representing about 1,018.4% upside from its current price of $0.76.Amount of Analyst CoverageNeuroSense Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about NeuroSense Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for NeuroSense Therapeutics are expected to decrease in the coming year, from ($0.40) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroSense Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroSense Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about NeuroSense Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.56% of the float of NeuroSense Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeuroSense Therapeutics has a short interest ratio ("days to cover") of 3.06, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroSense Therapeutics has recently decreased by 24.14%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuroSense Therapeutics does not currently pay a dividend.Dividend GrowthNeuroSense Therapeutics does not have a long track record of dividend growth. News and Social Media4.5 / 5News Sentiment1.18 News SentimentNeuroSense Therapeutics has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for NeuroSense Therapeutics this week, compared to 1 article on an average week.Search Interest5 people have searched for NRSN on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows3 people have added NeuroSense Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of NeuroSense Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $400,000.00 in company stock, which represents 1.6164% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, NeuroSense Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $400,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders27.40% of the stock of NeuroSense Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions1.04% of the stock of NeuroSense Therapeutics is held by institutions.Read more about NeuroSense Therapeutics' insider trading history. Receive NRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRSN Stock News HeadlinesNeuroSense Therapeutics (NRSN) Expected to Announce Earnings on TuesdayJune 23 at 1:10 AM | americanbankingnews.comEverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the DotsJune 22 at 9:00 AM | prnewswire.comBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.June 24 at 1:00 AM | Awesomely, LLC (Ad)NeuroSense Therapeutics (NASDAQ:NRSN) CEO Alon Ben-Noon Purchases 250,000 SharesJune 18, 2026 | insidertrades.comNeuroSense Granted South Korean Patent Covering PrimeC Composition for ALSJune 11, 2026 | prnewswire.comNeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel CompositionJune 9, 2026 | prnewswire.comNRSN Share News TodayMay 19, 2026 | uk.investing.comNeuroSense Announces Pricing of Insider-Led PIPE FinancingApril 28, 2026 | prnewswire.comSee More Headlines NRSN Stock Analysis - Frequently Asked Questions How have NRSN shares performed this year? NeuroSense Therapeutics' stock was trading at $0.7690 at the beginning of 2026. Since then, NRSN shares have decreased by 1.2% and is now trading at $0.76. How were NeuroSense Therapeutics' earnings last quarter? NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) released its quarterly earnings results on Monday, April, 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.06. When did NeuroSense Therapeutics IPO? NeuroSense Therapeutics (NRSN) raised $13 million in an initial public offering on Wednesday, December 8th 2021. The company issued 2,000,000 shares at $6.00-$7.00 per share. Who are NeuroSense Therapeutics' major shareholders? NeuroSense Therapeutics' top institutional investors include Yorkville Advisors Global LP (0.24%). Insiders that own company stock include Alon Ben-Noon and Or Eisenberg. View institutional ownership trends. How do I buy shares of NeuroSense Therapeutics? Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeuroSense Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroSense Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Abbott Laboratories (ABT) and Energy Select Sector SPDR Fund (XLE). Company Calendar Last Earnings4/07/2025Today6/24/2026Next Earnings (Estimated)6/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 NRSN's financial health is in the Red zone, according to TradeSmith. NRSN has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NRSN CIK1875091 Webwww.neurosense-tx.com Phone972-9799-6183FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for NeuroSense Therapeutics$8.50 High Price Target$14.00 Low Price Target$3.00 Potential Upside/Downside+1,018.4%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.31 Quick Ratio0.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-15.20Miscellaneous Outstanding Shares32,560,000Free Float23,636,000Market Cap$24.75 million OptionableNot Optionable Beta1.56 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:NRSN) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersFirm That Predicted 2008, 2020, 2022: Right Now Looks WorseThe firm that predicted the dot-com crash, the 2008 financial crisis, the 2020 COVID crash, and the 2022 bear ...TradeSmith | SponsoredThe Treasury just bought its own debtOn April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...Golden Portfolio | SponsoredElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | Sponsored“The unseen winner of the AI race” is not SpaceXMarc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...Chaikin Analytics | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
